Company profile
ABIVAX S.A.
NASDAQ:ABVXBiotechnology: Pharmaceutical Preparations
Drug pipeline (2)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| OBEFAZIMOD | phase3 | — | 20 | active |
| ABX-196 | phase1_2 | — | 1 | no active trials |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (23)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT02990325 | phase1_2 | completed | 2017-03-27 | 2018-12-27 | Abivax S.A. | A Safety, Pharmacokinetics, and Pharmacodynamics Study of ABX464 in HIV-1 Seronegative and Seropositive Adults |
| NCT05535946 | phase3 | active_not_recruiting | 2023-01-16 | 2026-04-28 | Abivax S.A. | ABTECT - Maintenance |
| NCT05507203 | phase3 | completed | 2022-11-16 | 2025-06-24 | Abivax S.A. | ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1 |
| NCT05507216 | phase3 | completed | 2023-01-25 | 2025-06-24 | Abivax S.A. | ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2 |
| NCT03897543 | phase1_2 | completed | 2020-02-18 | 2022-04-14 | Abivax S.A. | ABX196 in Combination With Nivolumab in Patients With Hepatocellular Carcinoma |
FDA applications (0)
No records yet.